{
    "thread": {
        "uuid": "2b938cbb637f8688eca72ab0e945cc8ad0a47925",
        "url": "https://in.marketscreener.com/quote/stock/COCRYSTAL-PHARMA-INC-44548736/news/Cocrystal-Pharma-LSINW-Presentation-49695448",
        "site_full": "in.marketscreener.com",
        "site": "marketscreener.com",
        "site_section": "http://in.marketscreener.com/news/most-read/",
        "site_categories": [],
        "section_title": "Today&#039;s best articles | MarketScreener India",
        "site_title": null,
        "title": "Cocrystal Pharma : LSINW Presentation | MarketScreener India",
        "title_full": "Cocrystal Pharma : LSINW Presentation | MarketScreener India",
        "published": "2025-04-24T00:18:00.000+03:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "IN",
        "main_image": "https://in.marketscreener.com/images/twitter_MS_fdblanc.png",
        "performance_score": 0,
        "domain_rank": 3557,
        "domain_rank_updated": "2025-04-22T00:00:00.000+03:00",
        "licensing_agency": [],
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "2b938cbb637f8688eca72ab0e945cc8ad0a47925",
    "url": "https://in.marketscreener.com/quote/stock/COCRYSTAL-PHARMA-INC-44548736/news/Cocrystal-Pharma-LSINW-Presentation-49695448",
    "ord_in_thread": 0,
    "author": "MarketScreener India",
    "published": "2025-04-24T00:18:00.000+03:00",
    "title": "Cocrystal Pharma : LSINW Presentation | MarketScreener India",
    "text": "Potent antivirals to combat some of the most serious diseases facing humanity\nLife Science Innovation Northwest April 2025\nNasdaq: COCP\nwww.cocrystalpharma.com\nAbout Cocrystal Pharma\nApplying powerful, proprietary drug discovery platform technology to develop first- and best-in-class broad-spectrum antiviral drugs\n3\nAdvancing programs in high-value antiviral drug targets\nNorovirus Influenza Coronavirus and respiratory viruses Drug candidates with clinically validated mechanisms of action\nEffectively cure viral diseases Broad-spectrum and potent antiviral activity Designed to be effective for emerging variants and existing drug-resistant viruses Multiple routes of administration (oral, inhalation, and injectable) Proprietary drug discovery platform technology\nUnique drug discovery platform technology developed with Nobel Prize-winning technology 3\nCocrystal's Structure-Based Drug Discovery Platform Technology For Pan-Viral Direct Acting Antiviral Development\nCocrystal technology uniquely offers:\nSystematic analysis of drug binding pockets Rapid cocrystal structure determination Structural insight into drug resistance Novel structural hits and pockets Multiple leads Cocrystal pan-viral inhibitors target highly\nconserved viral protease active site\nSARS-Cov-2 SARS-Cov-1 MERS-CoV Norovirus\nHRV\nEnterovirus\nEnterovirus Coxsackie virus\nD68\nA71\n4\nRobust Pipeline Addressing Unmet Medical Needs\nMultiple clinical assets poised to deliver significant growth\nProgram\nCandidate\nDiscovery\nPreclinical\nPhase 1\nPhase 2\nPhase 3\nNorovirus &\nOral Pan-viral\nprotease inhibitor\nCoronavirus\nCDI-988\nNorovirus\nReplication inhibitors\nRespiratory viruses\nPan-viral inhibitors\nOral PB2 inhibitor\nInfluenza A\nCC-42344\nInhaled PB2 inhibitor\nCC-42344\nInfluenza A/B\nReplication inhibitors\n5\n5\nNorovirus Infection : No Approved Treatments or Vaccines Available\nCruise ships\nRestaurants\nNorovirus\nNursing homes\nMilitary\nSchools\nBronson Norwalk Elementary School\n6\nNorovirus Viral Gastroenteritis Represents a Large Global Market: $72.7 Billion by 2032\nNo treatment or vaccines available\n7\n* Market Research Future , Viral Gastroenteritis , 2023\nCDC: Norovirus Disease in the United States https://www.cdc.gov/norovirus/burden.html\n7\n7\nCocrystal's pan-viral protease inhibitor, CDI-988:\nFirst-in-class antiviral for norovirus Potential for both prevention and treatment Phase 1 SAD and MAD studies complete Human challenge study planned in 2025 Confidential\nBig Surge of Norovirus Outbreaks in 2024-2025 After COVID-19 Pandemic\n2024-2025 norovirus outbreaks\n8\n8\nReference: Science, 13 January 2025\nConfidential\nNorovirus GII.17 Variants Become Dominant :\n>70% Responsible For Recent Norovirus Outbreaks\nGII.17\nCOVID\nGII.4\nCOVID\nhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.39.2400625\n9\n9\nConfidential\nPan-Viral Protease Inhibitor CDI-988 For Norovirus GII.4 and GII.17 and COVID\n(A) SARS-CoV-2\n• First-in-class antiviral for norovirus\nCDI-988\n• Developed using Cocrystal's proprietary\ndrug discovery platform technology\n• Binds to a highly conserved region required\nfor viral proteases\n(B) Norovirus\n• Exhibits pan-viral activity against pandemic\nnorovirus and SARS-CoV-2, SARS-CoV, and\nGII.4\nGII.17\nMERS-CoV strains\n• Phase 1 complete\n• One molecule, multiple indications\nCocrystal structures of norovirus proteases with CDI-988\n10\n10 10\nAttention : This is an excerpt of the original content. To continue reading it, access the original document here . Attachments\nOriginal document Permalink Disclaimer\nCocrystal Pharma Inc. published this content on April 23, 2025 , and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) , unedited and unaltered, on April 23, 2025 at 21:17 UTC .\nShare © Publicnow - 2025",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
        "Health",
        "Science and Technology",
        "Economy, Business and Finance"
    ],
    "topics": [
        "Health->drug rehabilitation",
        "Health->health organisation",
        "Health->health treatment and procedure",
        "Science and Technology->medical research",
        "Science and Technology->biomedical science",
        "Economy, Business and Finance->healthcare industry",
        "Economy, Business and Finance->business information",
        "Economy, Business and Finance->financial and economic news"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [
        "https://twitter.com/intent/tweet?text=Cocrystal",
        "https://www.cdc.gov/norovirus/burden.html",
        "https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Cocrystal",
        "https://wa.me/?text=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dwhatsapp%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
        "https://telegram.me/share/url?url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dtelegram%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
        "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
        "https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.39.2400625",
        "https://www.wa.me/?text=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dwhatsapp%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
        "https://www.telegram.me/share/url?url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dtelegram%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
        "https://telegram.me/share/url",
        "https://eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.39.2400625",
        "https://wa.me/",
        "https://www.facebook.com/sharer/sharer.php",
        "https://www.linkedin.com/shareArticle",
        "https://www.twitter.com/intent/tweet?text=Cocrystal",
        "https://twitter.com/intent/tweet",
        "https://facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
        "https://linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FCOCRYSTAL-PHARMA-INC-44548736%2Fnews%2FCocrystal-Pharma-LSINW-Presentation-49695448%2F%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Cocrystal",
        "https://cdc.gov/norovirus/burden.html"
    ],
    "entities": {
        "persons": [],
        "locations": [],
        "organizations": [
            {
                "name": "CC",
                "sentiment": "none",
                "tickers": [
                    {
                        "ticker": "CC",
                        "exchange": "NYSE"
                    }
                ]
            }
        ]
    },
    "syndication": {
        "syndicated": false,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "trust": {
        "categories": [],
        "bias": null,
        "source": {
            "type": null,
            "city": null,
            "state": null,
            "country": null,
            "domain_type": null,
            "agency": null,
            "organization_name": null
        }
    },
    "rating": null,
    "crawled": "2025-04-24T00:25:10.912+03:00",
    "updated": "2025-04-24T00:25:10.912+03:00"
}